Advancing Drug-Drug Interaction Science with Certara

Welcome to the April edition of the Inner Circle! 

This month’s issue spotlights one of the most critical challenges in drug development: drug-drug interaction (DDI) science. DDIs can significantly impact the safety and efficacy of investigational therapies, and Certara brings deep scientific expertise, industry-leading modeling platforms, and regulatory insight to help our partners navigate this complex area with confidence.

 While our primary focus is DDI science, we’re also sharing resources on a recent rgulatory development that’s sparked significant client interest: the FDA’s recent announcement to phase out animal testing requirements for monoclonal antibodies and other select therapies. This shift is accelerating the adoption of New Approach Methodologies (NAMs), including in silico tools and computational modeling—areas where Certara has unique technologies, expertise and insights.  

We invite you to learn more about this trending topic through two upcoming opportunities:

• Join our April 30th webinar to hear how our scientists are helping clients respond with our new Non-Animal Navigator™solution.

• Attend Certainty US, our client community event, to dive deeper into this and other regulatory trends impacting drug development today.

Wishing you a wonderful spring!

White Paper

Assessing Transporter-Mediated DDIs

Learn strategies to evaluate transporter-mediated DDIs, assess clinical significance, and determine when clinical DDI studies are necessary. This guide highlights how Certara’s DIDB platform simplifies these processes using in vitro and clinical datasets.

Read more

Blog Post

Measuring Metabolites in Clinical DDI Studies

Explore how measuring substrate metabolites enhances DDI detection and the ROI of clinical pharmacology programs. Discover why knowing when to measure metabolites is key to achieving accurate predictions of DDI risk.

Read now

On-Demand Webinar

Optimize DDI Knowledge Throughout Drug Development

Certara's Drug Interaction Database (DIDB) is the industry’s largest scientist-curated database to assess drug interactions and safety. Learn how DMPK scientists, clinical pharmacologists, and other researchers are using DIDB to optimize drug interaction decision making at every stage of development.

Watch now

Article

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Discover how a PBPK model for adagrasib, a covalent inhibitor of the G12C-mutated KRAS protein used in treating non-small cell lung cancer in adults, predicted potential drug-drug interactions, provided dosing recommendations, and influenced the adagrasib program and labeling.

Read more

On-Demand Webinar

Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions

Over the past 25 years, PBPK modeling has transformed drug-drug interaction research. It has improved prediction accuracy and provided deeper mechanistic insights. This shift has also fostered a more collaborative and innovative research culture, as explored further in this on-demand webinar.

Watch now

Take the Next step

Stay informed and ahead in drug development by leveraging Certara’s cutting-edge tools and expertise. Don’t miss vital updates that could transform your workflows.

Together, we can simplify the complexities of drug interactions and drive innovation in drug development.

Check out more resources on DDI Science

Explore where to connect with Certara next:

Asembia AXS25 Summit

April 27 - May 1 | Las Vegas, NV | Booth #1523  | Learn more

EMWA Spring Conference

May 6 - 9 | Riga, Latvia | Learn more

PharmaSUG 2025

June 1 - 4 | San Diego, CA | Booth #306 | Learn more

PAGE 2025

June 4 - 6 | Thessaloniki, Greece | Booth #11 & #12 | Learn more

DIA Annual Meeting 2025

June 15 - 19 | Washington DC | Booth #1831 | Learn more

Register now to attend live Certara webinars:

Unlocking the Power of Oligonucleotide Therapeutics: A Model-Informed Approach with Certara & Ionis

April 29, 2025 | 11am EST | Register

Are you prepared for the FDA’s phase out of animal tests for mAbs?

April 30, 2025 | 11am EST | Register

eCTD 4.0: When & Where it will be Implemented Next

May 14, 2025 | 10am EST / 2pm GMT | Register

MBMA for Relative Treatment Effects and Absolute Outcomes: A Focus on Concepts and Applications 

May 27, 2025 | 11am EST | Register